<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136229">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01984580</url>
  </required_header>
  <id_info>
    <org_study_id>F/N-R-11-3038L</org_study_id>
    <nct_id>NCT01984580</nct_id>
  </id_info>
  <brief_title>Effect of Zinc on Barrett's Metaplasia</brief_title>
  <official_title>Effect of Zinc on Barrett's Metaplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Main Line Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sharpe-Strumia Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Main Line Health</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using orally administered zinc to patients already diagnosed with the pre-cancerous
      condition, Barrett's Esophagus, this study is asking two questions:

        1. can this zinc administration cause molecular-level changes in the Barrett's tissue?

        2. are the changes measured indicative of chemopreventive action by zinc regarding cancer
           progression?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      14 days prior to already-scheduled upper endoscopy (EGD) procedures for routine surveillance
      of Barrett's tissue, patients who have given written, informed consent are randomized
      (sealed envelope method) and placed on an oral dose of zinc gluconate (26.6 mg zinc BID) or
      a placebo (molar equivalent of sodium gluconate BID) for 14 days.  At the time of endoscopy,
      4 biopsies are taken (and pooled) from the Barrett's tissue and 4 from proximal normal
      esophageal tissue.  Biopsies are flash frozen for later analyses by atomic absorption
      spectroscopy, PAGE and Western immunoblot or RNA microarray.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Changes in zinc-regulated cellular proteins within Barrett's tissue</measure>
    <time_frame>in biopsy tissue after 14 days of Zn exposure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in cellular microRNA profile; changes in protein cancer biomarkers</measure>
    <time_frame>in biopsy tissue after 14 days of Zn exposure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Barrett's Metaplasia</condition>
  <arm_group>
    <arm_group_label>Zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sodium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zinc gluconate</intervention_name>
    <description>26.6 mg zinc BID (as zinc gluconate)</description>
    <arm_group_label>Zinc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:ages 18-80; prior diagnosis of Barrett's esophagus -

        Exclusion Criteria:unable to provide written, informed consent; prior history of Barrett's
        dysplasia or esophageal adenocarcinoma; drug exclusions: hormone replacement therapy,
        cholestyramine, amiloride diuretics, oral quinolone antibiotics, glucocorticoids,
        corticosteroids, anticoagulants (other than aspirin)

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>James M Mullin, Ph.D.</last_name>
    <phone>484-476-2708</phone>
    <email>mullinj@mlhs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lankenau Institute for Medical Research</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 8, 2013</lastchanged_date>
  <firstreceived_date>November 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Main Line Health</investigator_affiliation>
    <investigator_full_name>James M. Mullin, Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Barrett's esophagus</keyword>
  <keyword>Esophagus</keyword>
  <keyword>Adenocarcinoma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
